Does Kaiser Permanente Cover Evenity (Romosozumab)?

Kaiser Permanente's Formulary Position on Evenity

Kaiser Permanente operates a closed formulary system, meaning only drugs reviewed and approved by its internal Pharmacy and Therapeutics (P&T) committee are routinely dispensed through Kaiser facilities. Evenity (romosozumab-aqqg) occupies a specialty tier position within this system, restricted to patients meeting narrow clinical criteria for severe osteoporosis 1.

Unlike open-network insurers where any in-network provider can prescribe, Kaiser requires that the prescribing physician be a Kaiser-employed clinician. This means outside rheumatologists or endocrinologists cannot initiate Evenity coverage through Kaiser. The P&T committee bases its coverage decisions on the ARCH trial data published in the New England Journal of Medicine, which demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone at 24 months 2. Kaiser's internal clinical guidelines also reference the FRAME trial, which showed a 73% reduction in new vertebral fractures versus placebo at 12 months 3.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend romosozumab as a first-line option for patients at very high fracture risk 4. Kaiser's internal pathway, however, positions the drug after failure of other agents regardless of fracture risk severity.

Prior Authorization Criteria at Kaiser Permanente

The prior authorization process for Evenity at Kaiser is notably more restrictive than at most commercial insurers. Kaiser uses an internal-only pathway, meaning requests route through Kaiser's own utilization management department rather than an external pharmacy benefit manager 5.

To obtain approval, the prescribing Kaiser physician must typically document all of the following: a confirmed diagnosis of osteoporosis with a DXA T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip 6; a history of osteoporotic fracture or a FRAX 10-year major osteoporotic fracture probability exceeding 20%; documented intolerance, contraindication, or inadequate response to at least one bisphosphonate (alendronate or risedronate) used for a minimum of 12 months; and confirmation that the patient has no history of myocardial infarction or stroke within the preceding 12 months 7.

The cardiovascular screening requirement reflects the FDA boxed warning added to Evenity's label based on the ARCH trial finding that romosozumab was associated with a higher rate of adjudicated major adverse cardiac events (MACE) compared with alendronate (2.5% vs. 1.9% at the end of the open-label period) 2. Kaiser's internal guidelines treat this cardiovascular signal conservatively. Patients with any atherosclerotic cardiovascular disease history may face automatic denial 8.

Processing time for Kaiser prior authorizations typically runs 5 to 14 business days, longer than the 48-to-72-hour turnaround at most commercial PBMs.

Step Therapy Requirements

Kaiser Permanente enforces step therapy before approving Evenity. The required sequence typically proceeds through two levels before romosozumab becomes available.

Step one requires documented use of an oral bisphosphonate. Alendronate 70 mg weekly or risedronate 35 mg weekly for at least 12 months with either continued bone loss on follow-up DXA or new fracture despite adherence 9. Kaiser's pharmacy data systems can verify fill history internally, making it difficult to claim prior bisphosphonate failure without Kaiser dispensing records to support it.

Step two typically requires trial of denosumab (Prolia) 60 mg subcutaneously every 6 months for at least 12 months 10. The Endocrine Society's 2019 clinical practice guideline notes that denosumab is an appropriate first-line agent for patients at high fracture risk who cannot tolerate oral bisphosphonates 11. Kaiser aligns with this by positioning denosumab as the preferred injectable before escalation to romosozumab.

For patients who experienced rebound vertebral fractures after denosumab discontinuation, a documented phenomenon described in multiple case series 12, Kaiser may waive the second step requirement. This exception requires documentation from the treating Kaiser endocrinologist.

Zoledronic acid (Reclast) 5 mg IV annually may also satisfy step therapy at some Kaiser regions, particularly for patients with documented GI intolerance to oral bisphosphonates 13.

How to Appeal a Kaiser Permanente Denial

When Kaiser denies Evenity coverage, the appeal process follows a defined internal pathway before external options become available.

The first-level appeal goes to Kaiser Member Services. You must file within 60 days of the denial letter. Include the prescribing physician's letter of medical necessity, relevant DXA scan results showing a T-score of -2.5 or worse, documentation of prior treatment failures with dates and durations, and any fracture imaging 14. Kaiser must respond within 30 calendar days for standard appeals or 72 hours for expedited appeals involving urgent clinical need.

If the first-level appeal fails, request a second-level review by Kaiser's regional medical director. This review considers whether the denial conflicts with published clinical guidelines from the AACE or Endocrine Society 4.

The final external option is a state Independent Review Organization (IRO). Every state where Kaiser operates (California, Colorado, Georgia, Hawaii, Maryland, Oregon, Virginia, Washington, and the District of Columbia) mandates access to an IRO for denied claims 15. The IRO assigns a board-certified specialist unaffiliated with Kaiser to review the case. IRO overturn rates for specialty biologics range from 40% to 60% nationally based on published data from state insurance departments.

A peer-to-peer review between the prescribing physician and Kaiser's medical director can sometimes resolve denials before formal appeal. Request this within 10 days of the initial denial.

Cost and Financial Considerations

Evenity's wholesale acquisition cost is $1,825 per monthly injection, totaling $21,900 for the full 12-dose course 1. Within Kaiser's system, out-of-pocket costs depend on the member's specific plan tier.

Kaiser Medicare Advantage members may face specialty tier copays of 20% to 33% per injection, translating to $365 to $602 per month before any catastrophic coverage kicks in 16. Kaiser commercial HMO members in California typically see specialty copays of $150 to $250 per injection under most employer-sponsored plans.

The Amgen savings card (Evenity Complete) offers eligible commercially insured patients up to $1,500 off per injection. Kaiser pharmacies generally do not accept manufacturer copay cards because Kaiser's integrated model processes prescriptions through its own specialty pharmacy rather than external networks 17. Some patients have obtained Evenity through exception pathways at external specialty pharmacies with Kaiser authorization, allowing copay card use, but this requires explicit plan exception approval.

Amgen's patient assistance program (Amgen Safety Net Foundation) provides free Evenity to uninsured patients or those with household incomes below 400% of the federal poverty level 18. This program does not apply to Kaiser members because Kaiser considers them "insured" regardless of affordability concerns.

Clinical Evidence Supporting Coverage Requests

Building a strong prior authorization or appeal requires citing the specific trial data that supports romosozumab use in your clinical scenario.

The ARCH trial (N=4,093) compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone. At 24 months, the romosozumab-to-alendronate sequence reduced clinical fractures by 27% (HR 0.73; 95% CI 0.61-0.88; P<0.001) and hip fractures by 38% (HR 0.62; 95% CI 0.42-0.92) 2.

The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months (0.5% vs. 1.8%; P<0.001) 3. The STRUCTURE trial showed romosozumab produced significantly greater gains in hip BMD compared with teriparatide in patients transitioning from bisphosphonates 19.

Dr. Felicia Cosman, Professor of Medicine at Columbia University, stated in her 2020 Endocrine Society position paper: "Romosozumab represents a unique mechanism as a sclerostin inhibitor that both builds new bone and reduces resorption simultaneously, a dual effect not achieved by any other osteoporosis therapy" 20.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) guidelines recommend considering anabolic therapy first in patients with very high fracture risk, defined as recent fracture within 2 years, fractures while on approved therapy, multiple fractures, or extremely low T-scores (below -3.0) 21.

Regional Variations in Kaiser Coverage

Kaiser Permanente operates as separate regional entities, and coverage policies can differ between regions. Kaiser Northern California and Kaiser Southern California, the two largest regions, generally follow the same P&T committee decisions for specialty drugs 22.

Kaiser Colorado and Kaiser Northwest (Oregon/Washington) have historically been slightly more restrictive with osteoanabolic agents, sometimes requiring failure of both a bisphosphonate and denosumab plus teriparatide before approving romosozumab. Kaiser Mid-Atlantic (Maryland/Virginia/DC) tends to follow the standard two-step pathway.

Members transferring between Kaiser regions should be aware that a prior authorization approved in one region does not automatically transfer. New authorization must be obtained in the receiving region, though treatment continuity exceptions exist for patients mid-course 23.

If you are a Kaiser member facing persistent denial, consider whether your region's specific P&T policies differ from the national Kaiser formulary. Your regional Member Services department can provide the exact coverage criteria document for your area.

Timing Considerations for Romosozumab Treatment

Romosozumab's 12-month treatment window creates urgency around coverage decisions. The FDA label specifies a lifetime exposure limit of 12 monthly doses based on the observation that the bone-forming effect of sclerostin inhibition attenuates after 12 months as anti-drug antibodies develop 1.

Delays in prior authorization can compress the effective treatment window. If approval takes 6 weeks, the patient loses meaningful time during which fracture risk remains elevated 24. The Endocrine Society recommends that for imminent fracture risk (fracture within the past 2 years), treatment delays beyond 3 months represent clinically significant harm 11.

After completing the 12-month romosozumab course, patients must transition to an antiresorptive agent (bisphosphonate or denosumab) to maintain bone density gains. ARCH trial data showed that BMD gains were preserved and fracture reduction continued when alendronate followed romosozumab 2. The post-romosozumab transition drug typically requires its own separate authorization within Kaiser's system.

Patients with T-scores below -3.5 or those who have sustained hip fractures should request expedited prior authorization review. Kaiser's utilization management policy includes expedited pathways for conditions where standard processing timelines could result in irreversible harm 25.